Small molecule · developed by Rapport Therapeutics
RAP-219 is an orally administered tablet studied in focal seizures and focal epilepsy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07563881 | Phase 3 | Focal Seizure | Recruiting | RAPP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
EpilepsyFocal EpilepsyFocal Seizure
Updated Nov 15, 2026. Something wrong or missing? Report it on the RAPP page.
See RAPP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RAPP catalysts and pipeline →